Dr. Clarke on Melanoma Biopsies

Loren Clarke, MD
Published: Friday, Jul 25, 2014

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.

There are approximately 1.5 million biopsies performed in the United States each year for atypical moles, Clarke says. These biopsies are done to exclude the possibility of melanoma, though about 15% are difficult to diagnose.

The myPath test, developed by Myriad Genetics, is an objective 23-gene signature assay that helps in the differentiation of malignant melanoma and a benign nevus.

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.

There are approximately 1.5 million biopsies performed in the United States each year for atypical moles, Clarke says. These biopsies are done to exclude the possibility of melanoma, though about 15% are difficult to diagnose.

The myPath test, developed by Myriad Genetics, is an objective 23-gene signature assay that helps in the differentiation of malignant melanoma and a benign nevus.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x